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Indomethacin Sensitizes TRAIL-Resistant Melanoma
Cells to TRAIL-Induced Apoptosis through
ROS-Mediated Upregulation of Death Receptor 5
and Downregulation of Survivin
Anfernee Kai-Wing Tse1, Hui-Hui Cao1, Chi-Yan Cheng1, Hiu-Yee Kwan1, Hua Yu1, Wang-Fun Fong1 and
Zhi-Ling Yu1
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has attracted considerable attention owing to its
selective killing of tumor cells but not normal cells. Melanoma shows weak response to TRAIL because of its low
level of TRAIL death receptors. Here, we investigated whether indomethacin, a nonsteroidal anti-inflammatory
drug, can potentiate TRAIL-induced apoptosis in melanoma cells. We showed that indomethacin was capable of
promoting TRAIL-induced cell death and apoptosis in A375 melanoma cells. Mechanistically, indomethacin
induced cell surface expression of death receptor 5 (DR5) in melanoma cells and also in various types of cancer
cells. DR5 knockdown abolished the enhancing effect of indomethacin on TRAIL responses. Induction of the DR5
by indomethacin was found to be p53 independent but dependent on the induction of CCAAT/enhancer-binding
protein homologous protein (CHOP). Knockdown of CHOP abolished indomethacin-induced DR5 expression
and the associated potentiation of TRAIL-mediated cell death. In addition, indomethacin-induced reactive oxygen
species (ROS) production preceded upregulation of CHOP and DR5, and consequent sensitization of cells to
TRAIL. We also found that indomethacin treatment downregulated survivin via ROS and the NF-kB-mediated
signaling pathways. Interestingly, indomethacin also converted TRAIL-resistant melanoma MeWo and SK-MEL-5
cells into TRAIL-sensitive cells. Taken together, our results indicate that indomethacin can potentiate TRAIL-
induced apoptosis through upregulation of death receptors and downregulation of survivin.
Journal of Investigative Dermatology (2014) 134, 1397–1407; doi:10.1038/jid.2013.471; published online 12 December 2013
INTRODUCTION
Malignant melanoma is a highly aggressive and treatment-
resistant cancer, with increasing incidence and high mortality
rates worldwide. The long-term survival rate for patients with
metastatic melanoma is only 5% (Cummins et al., 2006).
Primary melanoma without any evidence of metastases is
mostly treated by surgery. Chemotherapeutic agents such as
dacarbazine and temozolomide (alkylating agents), vemura-
fenib (targeting the BRAF V600E mutation), ipilimumab (targeting
CTLA-4), interferon Alfa-2b, and IL-2 for melanoma are pre-
sently evolving (Julia et al., 2012; Ma and Armstrong, 2013);
however, they are not suitable for many patients because of
toxicity, lack of the BRAF V600E mutation, and/or development
of resistance (Julia et al., 2012; Ma and Armstrong, 2013).
Therefore, other treatment strategies are still required.
Tumor necrosis factor–related apoptosis-inducing ligand
(TRAIL) has attracted considerable attention owing to its selec-
tive killing of tumor cells but not normal cells (Pan et al.,
1997). Apoptosis induction by TRAIL is mediated by its
interaction with cognate death receptors, TRAIL-R1 (DR4)
and -R2 (DR5) (Abdulghani and El-Deiry, 2010). Melanoma
cells were previously reported to be variably susceptible to
TRAIL-induced apoptosis (Griffith et al., 1998; Nguyen et al.,
2001). However, intrinsic resistance to TRAIL, because of the
low TRAIL receptor expression levels, appears to be a major
barrier for the development of efficient therapies for mela-
noma (Nguyen et al., 2001; Ivanov et al., 2003; Zhang et al.,
2004). Moreover, Zhuang et al. (2006) revealed that decreased
expression of TRAIL receptors was associated with thick
primary melanoma and metastatic melanoma. Therefore,
therapeutic initiatives designed to upregulate TRAIL death
receptor expression levels have been proposed to be used in
combination with TRAIL for treating melanoma.
A number of reports have suggested that induction of
endoplasmic reticulum (ER) stress response within cancer cells
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could sensitize cancer cells to TRAIL through the induction of
DR5 expression (Mellier and Pervaiz, 2012; Siegelin, 2012). It
has been documented that CCAAT/enhancer-binding protein
homologous protein (CHOP), a transcription factor that is
upregulated following multiple stimuli, directly controls DR5
expression via a CHOP-binding site in DR5 promoter region
(Yamaguchi and Wang, 2004). Since that time, various reports
with different stress-inducing compounds have been shown to
modulate TRAIL-mediated apoptosis in different cancer cells
(Mellier and Pervaiz, 2012; Siegelin, 2012).
Indomethacin is a nonsteroidal anti-inflammatory drug that
has been widely used for reducing fever, as well as pain and
inflammation (Dubois et al., 1998). In addition, indomethacin
holds promise as a chemotherapeutic sensitizing agent to
enhance the cytotoxic effects of anticancer agents (Lala
and Parhar, 1988; Cipa´k et al., 2004; Jamshidi et al., 2008;
Yu et al., 2009). Moreover, indomethacin has also been
demonstrated to induce ER stress and consequently trigger
the expression of CHOP, which is responsible for its apoptotic
and anti-inflammatory activities (Tsutsumi et al., 2004;
Okamura et al., 2008; Franceschelli et al., 2011). However,
whether indomethacin can induce CHOP-dependent DR5
expression in melanoma cells is still unknown.
Given that indomethacin induces CHOP upregulation
(Tsutsumi et al., 2004; Okamura et al., 2008; Franceschelli
et al., 2011), the current study focused on addressing whether
indomethacin can induce DR5 expression in TRAIL-resistant
melanoma cells and, if it does, whether indomethacin can
also enhance TRAIL responses. We describe here that
indomethacin can potentiate TRAIL-induced apoptosis in
TRAIL-resistant melanoma cells through upregulating death
receptor DR5 via ROS-mediated CHOP activation and
through the downregulation of survivin.
RESULTS
Indomethacin sensitizes melanoma cancer cells to
TRAIL-mediated apoptosis
We first examined the cytotoxic effects of indomethacin alone
or in combination with TRAIL. A375 melanoma cells dis-
played low rates of TRAIL-induced cell death (Figure 1b, top).
However, pretreatment with indomethacin significantly
enhanced TRAIL-induced cytotoxicity, as determined by
MTT assay (Figure 1b, bottom) and crystal violet staining
(Supplementary Figure S1a online).
We also investigated whether indomethacin increases
TRAIL-induced activation of caspase-3, -8, and -9 and
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Figure 1. Indomethacin sensitizes TRAIL-induced apoptosis in A375 melanoma cells. (a) Chemical structure of indomethacin. (b) Cell viability was assessed by
the MTT assay. (c) Western blotting of lysates from A375 cells pretreated with indomethacin for 24 hours followed by treatment with tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) for 3 hours using the indicated antibodies. (d) Caspase activities in A375 cells that had been treated with indomethacin for
24 hours and then TRAIL for 8 hours. (e) Cells were stained with PI/Annexin V and then analyzed by FACS. a,b,cPo0.05 with a versus control, b versus
indomethacin and c versus TRAIL. (b, d) At least two independent experiments with triplicates revealed comparable results. (c, e) At least two independent
experiments revealed largely comparable results.
AK-W Tse et al.
Sensitization of TRAIL-Mediated Apoptosis by Indomethacin
1398 Journal of Investigative Dermatology (2014), Volume 134
consequent PARP cleavage. We found that indomethacin
enhanced TRAIL-induced activation of all 3 caspases, which
in turn led to increased PARP cleavage (Figure 1c). Combinatory
treatment of A375 with indomethacin and TRAIL also strongly
stimulated caspase-3 and caspase-8 activities (Figure 1d).
In addition, we found that indomethacin enhanced TRAIL-
induced cell death assayed by annexin V/PI staining
(Figure 1e). Furthermore, pretreatment of A375 cells with
indomethacin resulted in a markedly increased accumulation
of sub-G1 phase cells and apoptotic nuclei (Supplementary
Figure S1b and c online) upon TRAIL treatment. Taken
together, these results suggest that indomethacin enhances
TRAIL-induced apoptosis.
Indomethacin upregulates expression of death receptor DR5 and
contributes to the enhancement of TRAIL-induced cell death
TRAIL mediates its activity through the receptors DR4 and
DR5; therefore, we investigated whether indomethacin
potentiated TRAIL-induced apoptosis through the modulation
of DR5 and DR4 expression. Treatment of A375 cells with
indomethacin resulted in an increased protein expression of
DR5 but not DR4 in a dose- and time-dependent manner
(Figure 2a). We also found that indomethacin was able to
induce DR5 expression in various types of cancer cells
(Supplementary Figure S2a online) and enhanced TRAIL-
induced cytotoxicity in HepG2, HCT116, and HeLa cells
(data not shown), indicating that DR5 induced by indometha-
cin is probably not cell-type specific. We next analyzed the
cell surface expression of DR5 using flow cytometry analysis.
After treatment of indomethacin, the level of DR5 on the cell
surface increased (Figure 2b). Collectively, these results
indicate that indomethacin upregulates the expression of
DR5 on the cell surface.
Next we asked whether DR5 expression is induced by
indomethacin at the transcriptional level. Using reverse
transcriptase PCR (RT-PCR), we found that indomethacin
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Figure 2. Indomethacin-induced DR5 upregulation is essential for sensitization of TRAIL-mediated apoptosis. (a) Western blotting of DR5 and DR4 in
A375 cells. (b) Cell surface expression of death receptor 5 (DR5) in A375 cells treated with 300mM indomethacin for 24 hours was measured by flow cytometry
analysis. MFI, mean fluorescence intensity. (c) (Top) Reverse transciptase PCR (RT-PCR) product from A375 cells treated as indicated for 18 hours.
(Bottom) Real-time PCR analysis of DR5 mRNA. *Po0.05 versus control. (d) (Top) Cells were transfected with DR5 small interfering RNAs (siRNAs), and
cell extracts were prepared for western blot analysis of DR5 and PARP. (Bottom) After transfection with death receptor 5 (DR5) siRNA, A375 cells viability was
assessed by the MTT assay. *Po0.05. (e) siRNA-transfected cells were stained with PI/Annexin V and then analyzed by FACS. (a–e) At least two independent
experiments revealed largely comparable results. TRAIL, tumor necrosis factor–related apoptosis-inducing ligand.
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markedly upregulated DR5 mRNA expression in a dose-
dependent manner (Figure 2c), suggesting that indo-
methacin does modulate DR5 expression at the transcriptional
level.
We next examined whether the suppression of DR5 by
small interfering RNAs (siRNAs) could abrogate the sensitizing
effects of indomethacin on TRAIL-induced cytotoxicity and
apoptosis. Transfection of A375 cells with DR5 siRNAs
reduced indomethacin-induced DR5 expression (Figure 2d).
PARP cleavage and cytotoxicity induced by indomethacin
plus TRAIL was significantly inhibited in cells transfected with
DR5 siRNAs (Figure 2d). Moreover, the effect of indomethacin
on TRAIL-induced cell death was effectively abolished in cells
transfected with DR5 siRNAs (Figure 2e), whereas treatment
with control siRNA had no effect.
The resistance of melanoma cells to TRAIL was also
reported to mediate through downregulation of DR4
(Kurbanov et al., 2007), and apoptosis induced in A375 cells
by TRAIL alone mainly depends on DR4 signaling (Kurbanov
et al., 2005). We therefore also examined whether the
silencing of DR4 in addition to DR5 could abolish the sensitiz-
ing effects of indomethacin on TRAIL-induced cell death. Cell
death induced by TRAIL alone in A375 cells was strongly
inhibited by DR4 siRNA treatment (Supplementary Figure S2b
and c online), as expected from previously published data
(Kurbanov et al., 2005). In contrast, the combination effect
was particularly inhibited by DR5 siRNA (Supplementary
Figure S2c online). Thus, indomethacin appeared to mediate
a switch from mainly DR4 signaling to DR5. Taken together,
these results suggest that indomethacin-induced DR5 induc-
tion is critical for TRAIL-enhancing effects in A375 cells.
Indomethacin activates DR5 transcription in a CHOP-dependent
manner
It has been shown that the induction of DR5 can be mediated
through the activation of CHOP (Yamaguchi and Wang,
2004). In this study, we found that the protein expression of
CHOP was significantly increased by indomethacin treatment
in a time-dependent manner (Figure 3a, top panel). We further
found that indomethacin induced CHOP mRNA expression in
a dose-dependent manner (Figure 3a, middle panel). Pretreat-
ment of cells with transcriptional (actinomycin D) and
translational (cycloheximide) inhibitors blocked indometha-
cin-induced CHOP expression (Figure 3a, bottom panel),
indicating that CHOP induction occurs at both transcriptional
and post-transcriptional levels. Furthermore, treatment with
indomethacin was able to induce CHOP promoter activity
(Supplementary Figure S3a online). Together, these results
suggest that indomethacin regulates the transcription of
CHOP.
To determine whether CHOP activates DR5 promoter
activity, we first tested the effects of indomethacin on the
transactivation of reporter constructs with different lengths of
DR5 5’-flanking regions (Figure 3b, top). We observed that
indomethacin did not increase the luciferase activity of
pGL3-DR5 (þ 71, þ150, and þ293), whereas it did
significantly induce the luciferase activity of pGL3-DR5
(310, 80, þ 1) (Figure 3b, bottom), indicating that the
region between þ1 and þ71 is essential for indomethacin-
induced DR5 transactivation. Given that a CHOP-binding site
is located in this region (Yamaguchi and Wang, 2004), we
further examined the effects of indomethacin on the transac-
tivation of DR5 reporter constructs carrying wild-type or
mutated CHOP-binding sites. Whereas the promoter activity
of pDR5-310 was significantly increased by indomethacin
treatment, the promoter activity of pDR5-310DCHOP was not
enhanced by indomethacin (Figure 3c). Moreover, knock-
down of CHOP expression by siRNAs transfection significantly
inhibited indomethacin-induced DR5 upregulation (Figure 3d,
top left). In line with this, knockdown of CHOP significantly
attenuated the cytotoxicity (Figure 3d, top right) and cell death
(Figure 3d, bottom) induced by the combined treatment of
indomethacin and TRAIL. Taken together, these results suggest
that CHOP induction plays an essential role in both indo-
methacin-induced DR5 upregulation and indomethacin-
mediated TRAIL-induced cell death enhancement.
Previous studies reported that p53 can induce DR5 expres-
sion (Wu et al., 1997; Takimoto and El-Deiry, 2000; Burns
et al., 2001). Whether indomethacin-induced induction of
DR5 is mediated through p53 was examined using HCT116
cell lines that lack p53. Indomethacin induced DR5 in p53
parental and p53 knockout HCT116 cells (Supplementary
Figure S3b online). These results indicate that indomethacin-
induced upregulation of DR5 is independent of p53.
Indomethacin potentiates TRAIL-induced apoptosis through ROS
generation
Many reports have shown that ROS plays a critical role in both
DR5 upregulation and TRAIL-induced apoptosis (Mellier and
Pervaiz, 2012; Siegelin, 2012). Thus, whether ROS is needed
for potentiation of TRAIL-induced apoptosis by indomethacin
was examined. Indomethacin strongly induced H2O2 produc-
tion in A375 cells (Figure 4a). In contrast, pretreatment with
antioxidant N-acetyl-L-cysteine (NAC) effectively blocked
H2O2 production induced by indomethacin (Figure 4a, left
panel). We also found that indomethacin increased super-
oxide (O2
 ) production (Figure 4a, right panel). Recently,
reports have revealed that ROS induces upregulation of
CHOP, leading to DR5 induction (Kim et al., 2008;
Yokouchi et al., 2008; Moon et al., 2011). Therefore, we
next determined whether ROS is involved in indomethacin-
induced CHOP and DR5 expression. As shown in Figure 4b,
pretreatment of cells with NAC reduced the indomethacin-
induced CHOP and DR5 upregulation. Under these condi-
tions, NAC also suppressed the enhancement effect of indo-
methacin on TRAIL-induced cell death (Figure 4c) and PARP
cleavage (Figure 4d). To further confirm the critical role of
H2O2 and O2
 in indomethacin-induced DR5 expression, we
performed DR5 promoter studies with the overexpression of
catalase or SOD1. Indomethacin-mediated DR5 promoter
activity was significantly blocked by the overexpression of
catalase or SOD1 (Figure 4e and Supplementary Figure S4
online), suggesting the essential role of H2O2 and O2

induction in indomethacin-mediated DR5 upregulation. Taken
together, these data clearly indicate that ROS generation
induced by indomethacin is critical for the upregulation of
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CHOP and DR5, contributing to indomethacin-stimulated
TRAIL-induced cell death and apoptosis.
Downregulation of survivin is involved in indomethacin-
stimulated TRAIL-induced apoptosis
A number of anti-apoptotic proteins such as survivin, XIAP,
Mcl-1, cIAP-1, cIAP-2, cFLIP, Bcl-2, bax, bak, and Bcl-xL have
been shown to be responsible for the TRAIL resistance
(Dimberg et al., 2013). Therefore, we examined whether
indomethacin sensitized TRAIL-induced cell death through
modulation of these cell survival proteins. We found that
indomethacin inhibited the expression of survivin but had no
apparent effect on the expression of other anti-apoptotic
proteins (Figure 5a). The downregulation of survivin by
indomethacin was in a dose- and time-dependent manner
(Supplementary Figure S5a online). We also found that
indomethacin caused a significant decrease (0.581 fold) in
survivin mRNA levels (data not shown). Previous studies found
that survivin could confer TRAIL resistance in melanoma
cells (Chawla-Sarkar et al., 2004; Li et al., 2005; Hilmi
et al., 2008). Whether survivin downregulation is needed for
potentiation of TRAIL-induced apoptosis by indomethacin was
examined. Ectopic expression of survivin partially rescued
indomethacin-stimulated PARP cleavage (Figure 5b) and
caspase-3 activity (Supplementary Figure S5b online) in
TRAIL-treated A375 cells, demonstrating that TRAIL-sensitizing
effects of indomethacin are partially mediated by the down-
regulation of survivin.
To determine the mechanism of survivin downregulation, we
first tested whether NAC can abrogate the indomethacin-
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Figure 3. Induction of CHOP is required for indomethacin-induced DR5 expression. (a) (Top) Western blotting of CHOP; (middle) RT-PCR analysis of
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induced downregulation of survivin. We found that NAC
partially reversed the indomethacin-induced suppression of
survinin (Figure 5c), indicating the involvement of ROS in
observed survivin downregulation. A previous study showed
that NF-kB could transactivate survivin gene promoter
(Kawakami et al., 2005). To test this possibility, we assessed
whether indomethacin would suppress NF-kB activity. We
observed that indomethacin inhibited nuclear translocation of
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NF-kB p65 without altering total p65 levels (Figure 5d). Ectopic
expression of p65 by transient transfection significantly blocked
the downregulation of survivin induced by indomethacin
treatment (Figure 5e). Interestingly, indomethacin treatment
markedly reduced the NF-kB-dependent luciferase activity,
and pretreatment with NAC did not reduce this inhibitory effect
(Figure 5f). Taken together, these results suggest that indo-
methacin-induced ROS generation and NF-kB inhibition inde-
pendently mediate survivin downregulation and contribute to
indomethacin-stimulated TRAIL-induced apoptosis.
Indomethacin sensitizes TRAIL-resistant melanoma cells
It has been shown that some melanoma cells such as Mewo
and SK-MEL-5 cells are completely resistant to TRAIL
(Kurbanov et al., 2005; Chen et al., 2012). As expected,
both MeWo and SK-MEL-5 cells had no responses to TRAIL
treatment alone (Figure 6a). Pretreatment with indomethacin
significantly enhanced TRAIL-induced cell death as deter-
mined by MTT assay (Figure 6a) and crystal violet staining
analysis (Supplementary Figure S6a online). We also found
that indomethacin induced upregulation of DR5 in these cells
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(Figure 6b). Results of flow cytometry analysis also revealed the
increase in DR5 cell surface expression in both cell lines
(Figure 6c). Further, we found that pretreatment of both cell
types with indomethacin resulted in a markedly increased
accumulation of apoptotic nuclei (Supplementary Figure S6b
online) and PARP, caspase-8 and caspase-3 cleavages
(Figure 6d), and cell death (Figure 6e) under TRAIL treatment.
Mechanistically, indomethacin strongly induced ROS produc-
tion in MeWo and SK-MEL-5 cells (Supplementary Figure S6c
online), and pretreatment of cells with antioxidant NAC
reduced the indomethacin-induced CHOP and DR5 upregula-
tion and rescued survivin downregulation (Supplementary
Figure S6d online). Interestingly, indomethacin showed no
DR5 induction and enhancement of cytotoxic effect in human
epidermal melanocytes HEMn cells (Supplementary Figure S7
online). Overall, we found that indomethacin can also
enhance TRAIL-induced apoptosis in TRAIL-resistant mela-
noma cells associated with the ROS–CHOP-mediated upregu-
lation of DR5 expression.
DISCUSSION
Therapeutic strategies to restore TRAIL receptor levels are
urgently needed to overcome resistance of melanomas to
TRAIL. In this study, we demonstrate that indomethacin
effectively sensitizes human melanoma cells to TRAIL-induced
apoptosis through upregulation of DR5 via ROS signaling
pathways. Indomethacin-induced ROS mediates the expres-
sion of CHOP and further upregulation of DR5 via the CHOP-
binding element in the DR5 promoter. We also found that
indomethacin downregulated anti-apoptotic protein survivin
levels in a ROS- and NF-kB-dependent manner and therefore
facilitated indomethacin-stimulated TRAIL-induced apoptosis
(summarized in Figure 6f). Given that indomethacin is
employed as an anti-inflammatory agent clinically, the com-
bination of TRAIL and indomethacin may be an effective
cancer therapy that warrants additional study in vivo.
Our results indicated that indomethacin enhanced TRAIL-
induced apoptosis through ROS–CHOP–DR5 induction
pathway. We observed that abrogation of DR5 or CHOP
upregulation could not completely protect against TRAIL/
indomethacin-induced cell death (Figures 2d and 3d). This
effect was probably due to the cytotoxicity induced by
indomethacin alone as silencing of DR5 had no effect on
indomethacin-induced cell death (Figure 2d). The mechanism
of indomethacin-induced cell death in melanoma cells
requires further investigation. Our results clearly showed that
silencing of DR5 or CHOP effectively blocked the cell death
induced by TRAIL/indomethacin (Figures 2e and 3d), but the
blocking effects were not completely. This phenomenon can
be explained by (i) incomplete knockdown of DR5 in the cell
surface receptor level, (ii) change of TRAIL receptor respon-
siveness by indomethacin/TRAIL treatment. It has been
reported that basal TRAIL death receptor expression may not
correlate with TRAIL sensitivity (Wagner et al., 2007). In this
respect, enhancing effects targeting on TRAIL receptor
modification such as O-glycosylation or other TRAIL-DISC
components such as FADD, caspase-8 and FLIP are needed to
be considered and further investigated in future. We found
that ROS plays a critical role in the expression of DR5 induced
by indomethacin. Interestingly, overexpression of catalase
gave a lesser suppressive effect on DR5 promoter activity as
compared to SOD1 overexpression (Figure 4e). This phenom-
enon can be explained by the following: (i) overexpression of
catalase alone induced slight upregulation of DR5 promoter
activity, (ii) superoxide generation may be more critical for
CHOP/DR5 induction by indomethacin. Further investigation
is needed to clarify the individual role of superoxide and
hydrogen peroxide in indomethacin-induced ER stress and
CHOP upregulation. CHOP is a typical ER stress–regulated
protein that is involved in ER stress–induced apoptosis.
Previous studies reported that indomethacin-induced ROS
production and CHOP induction are involved in its apoptotic
and anti-inflammatory activities (Tsutsumi et al., 2004;
Okamura et al., 2008; Franceschelli et al., 2011). Our data
indicate that indomethacin can trigger ER stress in melanoma
cells. The mechanism underlying indomethacin-induced
CHOP upregulation via the ROS pathway during ER stress
needs further investigation. In previous studies, it has been
suggested that induction of DR5 can be mediated through the
p53 intronic binding site in DR5 promoter (Wu et al., 1997;
Takimoto and El-Deiry, 2000; Burns et al., 2001). However,
we found that DR5 was induced by indomethacin through a
p53-independent mechanism, as determined using HCT116
p53 knockout cells (Supplementary Figure S3b online).
Indeed, indomethacin did not upregulate, but rather slightly
downregulated, the expression of p53 (Supplementary Figure
S3b online). Moreover, indomethacin was able to induce DR5
expression in p53-mutated MeWo melanoma cells (Zo¨lzer
et al., 1995) (Figure 6b), p53-deleted cells (SKOV3), and in
various p53-mutated (BxPC-3, OVCAR3, MDA-MB-231, HT-
29) cell lines (Supplementary Table S1 online shows p53 status
of cell lines used in this study), further suggesting that p53 is
not involved in indomethacin-induced DR5 upregulation.
Inhibitors of apoptosis proteins (IAPs) such as XIAP, cIAP-1,
cIAP-2, and survivin are important determinants of TRAIL-
induced apoptosis in mitochondria-dependent type II cancer
(Zhang and Fang, 2004). In this study, we found that
indomethacin inhibited survivin expression (Figure 5a), and
this contributed to the indomethacin-stimulated apoptotic
effect of TRAIL (Figure 5b). Our data showed that transient
transfection of Flag-tagged survivin only partially protected
against indomethacin/TRAIL-induced PARP-1 cleavage
(Figure 5b) and caspase-3 activity (Supplementary Figure S5b
online). Further studies by stably overexpression of survivin in
A375 cells are needed to confirm whether survivin can
completely protect the indomethacin-induced TRAIL enhance-
ment effect. It has been shown that downregulation of survivin
by chemotherapeutic agents can be abolished by the anti-
oxidant NAC (Prasad et al., 2010, 2011; Sung et al., 2012).
Interestingly, we found that the effect of indomethacin on
survivin was mediated through ROS and that NAC reversed the
downregulation (Figure 5c). Indomethacin has been reported to
reduce survivin expression in gastric mucosal and epithelial
cells through proteasome degradation (Chiou et al., 2005;
Chiou and Mandayam, 2007). Consistent with these findings,
we found that survivin downregulation occurred at both
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protein (Figure 5a) and mRNA levels (data not shown) in A375
melanoma cells. Further studies are, however, needed to
determine the possible involvement of proteasome degradation
of survivin by indomethacin in melanoma cells.
Many reports have shown that indomethacin can inhibit
NF-kB activity (Takada et al., 2004; Preciado et al., 2005;
Shen et al., 2007). Consistent with previous findings, in our
system we found that indomethacin inhibited p65 nuclear
translocation in A375 melanoma cells (Figure 5d). We also
showed that survivin protein expression was downregulated
by indomethacin treatment through inhibition of the NF-kB
signaling pathways, in which the introduction of ectopic p65
restored the protein levels of survivin to almost basal levels in
indomethacin-treated cells (Figure 5e). The detailed mechan-
ism of how indomethacin inhibits NF-kB is still not fully
understood. Using the NF-kB luciferase reporter assay, we
determined that the NF-kB inhibitory effect by indomethacin
was not caused by ROS signaling (Figure 5f). Collectively, the
results of this study reveal that indomethacin-induced ROS
generation and NF-kB inhibition mediate survivin downregu-
lation by indomethacin and contribute to enhancement of
TRAIL responses.
Recently, many studies have shown sensitization effects of
melanoma cells for TRAIL-induced apoptosis with different
mechanisms including phosphorylation and activation of Bax
(Berger et al., 2013a), RAF inhibition (Berger et al., 2013b),
enhancement of both extrinsic and intrinsic apoptosis pathways
(Berger et al., 2011), and SMAC release (second mitochondria–
derived activator of caspases) (Quast et al., 2012). Moreover,
NASIDs other than indomethacin such as acetylsalicylic acid,
sodium salicylate, diclofenac, and hyaluronic acid have been
shown to enhance TRAIL-induced apoptosis in skin-related
cancer through downregulation of c-FLIP (Braun et al., 2012;
Fecker et al., 2012). In this study, we found that NASID
indomethacin enhanced DR5 expression and increased
TRAIL-induced apoptosis. Therefore, it is interesting to investi-
gate whether a combination of these TRAIL-sensitizing agents
would provide further dramatic effects on TRAIL-induced
apoptosis in melanoma cells. Moreover, we observed that
indomethacin treatment caused a marginal decrease in the
cFLIP expression level (Figure 5a). As previous reports showed
that downregulation of cFLIP is sufficient to sensitize mela-
noma cells to TRAIL (Geserick et al., 2008; Braun et al., 2012;
Fecker et al., 2012), it is possible that this minor reduction of
cFLIP level by indomethacin may also influence the TRAIL
responses. More prudent experiments will be needed to
investigate the role of cFLIP in the TRAIL-sensitizing activity
by indomethacin. We also found that indomethacin showed a
basal cytotoxic effect in human melanocytes but no increase
in both DR5 level and sensitivity to cell death in the presence
of TRAIL (Supplementary Figure S7 online). Thus, it is inter-
esting to determine the effects of indomethacin in the ROS–
CHOP pathway in human melanocytes and whether a higher
dose of indomethacin is needed to increase the DR5 levels of
human melanocytes in future.
In conclusion, we show that indomethacin can effectively
restore TRAIL sensitivity in melanoma cells by either:
(1) upregulation of DR5 and/or (2) downregulation of survivin,
a well-known inhibitor of apoptosis. Furthermore, ROS gen-
erated by indomethacin plays a critical role in CHOP-
mediated DR5 upregulation, and ROS and NF-kB signaling
pathways are important for the downregulation of survivin
protein expression. As indomethacin is used clinically, animal
studies are warranted to explore the combined effects of
indomethacin and TRAIL, with the goal of providing safe
and effective treatment regimens for melanoma.
MATERIALS AND METHODS
Western blot analysis
Whole-cell protein and nuclear lysates were prepared and analyzed
by western blotting as described previously (Tse et al., 2005).
Analysis of cell surface DR5
Cells were detached with 0.5 mM EDTA and then stained with
phycoerythrin-conjugated mouse monoclonal anti-human DR5 or
isotype control, and incubated for 60 minutes at 4 1C. Surface
expression of DR5 was determined by flow cytometry. phycoery-
thrin-conjugated mouse anti-human DR5 (DJR2-4) and phycoery-
thrin-mouse IgG1 isotype control (MOPC-21) were purchased from
BioLegend (San Diego, CA).
MTT cytotoxicity assay and crystal violet staining
Cytotoxicity was determined by the MTT uptake method (Yang et al.,
2011). For crystal violet staining assay, cells (1 105) were seeded in
60 mm dishes, and then untreated or pretreated with indomethacin
for 24 hours, washed with phosphate-buffered saline, and then treated
with TRAIL. After 5 days, the cells were stained with crystal violet.
siRNA treatment
Silencing of DR4, DR5, or CHOP was achieved by transfecting siRNAs
(Dharmacon, Lafayette, CO) using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s recommendations.
Gene silencing effect was evaluated by western blot analysis.
Construction of plasmids, transient transfection, and luciferase
activity assay
All DR5 luciferase promoter regions were cloned into pGL3-Basic
vector. The NF-kB luciferase reporter (pNF-kB-Luc) was obtained
from Clontech (Mountain View, CA). SOD1, catalase, and survivin
full-length expression constructs were synthesized by PCR using A375
total mRNA and subcloned into the pcDNA3-Flag tagged vector. The
plasmid transfection and luciferase assay were the same as described
previously (Tse et al., 2005). Firefly and renilla luciferase activities
were assayed according to the manufacturer’s protocol (Promega,
Madison, WI). Firefly luciferase activity was normalized to renilla
luciferase activity in cell lysate and expressed as an average of three
independent experiments.
Measurement of reactive oxygen species
Cells were plated in black 96-well plates and allowed to attach for
24 hours. Then cells were loaded with fluorescent dyes, 6-Carboxy-
2’,7’-dichlorofluorescein diacetate, or dihydroethidium, and further
stimulated with 300mM indomethacin with or without the pretreat-
ment of 5 mM NAC for 1 hour. Fluorescence was measured
using a fluorescence microplate reader (EnVision Multilabel Reader,
PerkinElmer, Waltham, MA) at the indicated time point at 37 1C.
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Asp-Glu-Val-Asp-ase (DEVDase) and Ile-Glu-Thr-Asp-ase
(IETDase) activity assays
DEVDase (caspase-3) or IETDase (caspase-8) activities were exam-
ined according to the protocol provided by caspase colorimetric
quantipak assay kit (Enzo Life Science, Farmingdale, NY).
Annexin V/PI assay
The indicator of cell death and apoptosis was detected by using
annexin V/PI binding kit (Abcam, Cambridge, MA). Briefly, A375 cells
were pretreated with 300mM indomethacin for 24 hours followed by
treatment with TRAIL (25 ng ml 1 for A375 and 50 ng ml 1 for
MeWo/SK-MEL-5) for 24 hours. Then, cells were trypsinized, stained
with annexin V/PI, and then analyzed with flow cytometer.
Statistical analyses
All data are expressed as mean±SD of three independent experi-
ments. Statistical significance was determined using unpaired
Student’s t-test and a P-value of less than 0.05 was considered
statistically significant.
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